Loading...
Market
Kymera's Disease Focus for KT-621 Post-Phase 1 by End of 2025
2
Resolution / Starting Odds
Asthma • 25%
Atopic Dermatitis • 25%
Allergic Rhinitis • 25%
Other • 25%
Kymera Therapeutics' official press releases or clinical trial registries
Story
Kymera ($KYMR) Reports Milestone in Phase 1 Trial for KT-621 STAT6 Degrader
Oct 25, 2024, 01:04 PM
Kymera Therapeutics has announced the dosing of the first participant in a Phase 1 clinical trial for KT-621, a first-in-class oral STAT6 degrader. KT-621 targets STAT6, a historically undrugged transcription factor in the IL-4/IL-13 signaling pathways, which is a central driver of T helper type 2 (TH2) inflammation in allergic diseases. The trial represents a significant milestone in the treatment of TH2 immuno-inflammatory diseases. KT-621 is designed to be taken once daily.
View original story
Similar markets
Significant improvement • 25%
Moderate improvement • 25%
No improvement • 25%
Worsening condition • 25%
Significant improvement • 25%
Moderate improvement • 25%
No improvement • 25%
Worse outcomes • 25%
Positive results • 25%
Negative results • 25%
Mixed results • 25%
Trial halted • 25%
BLA submission • 25%
Phase III trial initiation • 25%
Conditional approval • 25%
No progress • 25%
Highly positive • 25%
Moderately positive • 25%
Neutral • 25%
Negative • 25%
Less than 50% efficacy • 25%
50-69% efficacy • 25%
70-89% efficacy • 25%
90% or higher efficacy • 25%
Trial halted • 25%
Limited efficacy • 25%
Moderate efficacy • 25%
High efficacy • 25%
Phase II trial completion • 25%
Phase III trial commencement • 25%
FDA approval • 25%
None of the above • 25%
